Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients
Authors:
- Albert Pérez-IsidroAPAlbert Pérez-Isidro
- Marc XipellMXMarc Xipell
- Arturo LlobellALArturo Llobell
- Noemí De MonerNMNoemí De Moner
- Gema M. LledóGLGema M. Lledó
- Ricard CerveraRCRicard Cervera
- Sergio Prieto-GonzálezSPSergio Prieto-González
- Luis F. QuintanaLQLuis F. Quintana
- Gerard EspinosaGerard Espinosa
- Mila García-OrmaecheaMGMila García-Ormaechea
- Estíbaliz Ruiz-OrtizEREstíbaliz Ruiz-Ortiz
- Odette ViñasOVOdette Viñas
Open Access
- 6 February 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1295
Abstract
Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians’ personalised care decisions.Keywords
Funding Information
- Hospital Clínic de Barcelona (Emili Letang Award-2017)
This publication has 38 references indexed in Scilit:
- Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: Implications for the treatment of autoimmunityJournal of Autoimmunity, 2012
- Plasma cells in systemic lupus erythematosus: The long and short of it allEuropean Journal of Immunology, 2011
- Interferon‐α induces unabated production of short‐lived plasma cells in pre‐autoimmune lupus‐prone (NZB×NZW)F1 mice but not in BALB/c miceEuropean Journal of Immunology, 2011
- B cells in autoimmunityArthritis Research & Therapy, 2009
- Persistent expression of autoantibodies in SLE patients in remissionJournal of Experimental Medicine, 2006
- Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W MiceJournal of Experimental Medicine, 2004
- The classification of glomerulonephritis in systemic lupus erythematosus revisitedKidney International, 2004
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cellsJournal of Immunological Methods, 1983
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982